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1. Introduction
Leishmaniasis comprises a broad-spectrum of neglected vector-borne diseases ranging in 
severity from the self-healing but disfiguring and stigmatizing cutaneous lesions to mucocu-
taneous and fatal visceral manifestations, depending on the species and host characteristics. 
This syndrome primarily afflicts the impoverished population of low-income countries falling 
in the tropics and subtropics. Globally, 0.7–1.2 million new cases of cutaneous leishmaniasis 
(CL) occur every year while for visceral leishmaniasis (VL), 200,000–400,000 new cases and 
20,000–40,000 deaths are reported each year, with 95% of fatal cases occurring in only six 
countries, namely, India, Bangladesh, Sudan, South Sudan, Ethiopia and Brazil [1]. The dis-
ease is transmitted by the bite of female Phlebotomus sandflies that transmit the promastigotes, 
which are then transformed into amastigotes within the mammalian macrophages. The goal 
of World Health Organization is to eliminate this public health problem in the South-east 
Asia Region by 2020 [2]. Despite intensive research, live vaccines are the only effective vac-
cines till date against CL while none exists for the visceral form that is the most severe of the 
various clinical forms of leishmaniasis. Moreover, there is an upward trend in development 
of resistance to most of the currently available drugs [3]. The chemotherapeutic arsenal is 
associated with need for hospitalization and prolonged periods of treatment, coupled with 
high toxicity, which limits the application and patient compliance. Combinations of drugs 
have also been explored. Absence of vaccines, progressive emergence of HIV-Leishmania  
co-infection and relapse after treatment delineate the gravity of leishmaniasis affliction [4]. 
A recent report indicated relapse of post kala-azar dermal leishmaniasis (PKDL) 1 year after 
successful treatment of VL with miltefosine and paromomycin [5]. Antimony therapy is also 
not advised in elderly patients with CL due to severe adverse side effects [6]. The potential of 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
the visceralizing species, Leishmania donovani to cause localized cutaneous lesions is also not 
fully understood [7].
This chapter gives a brief glimpse of the recent advances in immunopathogenesis and immune 
evasion strategies employed by the Leishmania parasite, vaccination and immunotherapeutic 
approaches, natural product-based drugs, nanomedicines, therapeutic targets and diagnosis 
of leishmaniasis. We have included citations of the latest research articles presenting the most 
recent results.
2. Immunopathogenesis and immune evasion strategies
Invasion of host macrophages by Leishmania triggers a multitude of signaling circuits to elimi-
nate the pathogen. However, the parasite tries to subvert these defense mechanisms to create 
a safe haven for their survival. Leishmania secretes effector molecules to modulate the host 
immune transcriptome resulting in alterations in the host epigenome to alter cytokine and 
chemokine levels, their cross talks and downstream signaling hubs. This adversely affects the 
recruitment and activation of immune cells, respiratory burst and antigen presentation, lead-
ing to immune evasion. Leishmania amazonensis has been reported to induce histone deacety-
lase in infected macrophages, which contributes to down regulation of inducible nitric oxide 
synthase and subsequent parasite survival [8]. L. donovani infection causes hypoxic environ-
ment within the macrophages by activating hypoxia inducible factor-1α, that in turn up regu-
lates micro RNA-210, while down regulating NF-κB mediated pro-inflammatory immune 
responses, to establish a safe niche for their survival [9].
Leishmania have evolved stratagems to neutralize macrophage defensive arsenals, the very 
heart of the immune system’s defensive machinery, resulting in replication of the para-
sites within the phagolysosomal vacuoles of the infected macrophages. Unfolding of these 
host-pathogen interactions will help in development of effective drug targets that would 
enable to modulate the host immune system to ameliorate the pathogenesis of infection. 
Besides the host immune profile and the intrinsic parasite factors that may influence the 
clinical manifestations of the disease, Leishmania virus RNA 1 (LRV1) infecting Leishmania 
guyanensis has been implicated to contribute to immunopathogenesis of American tegu-
mentary leishmaniasis [10]. Studies have also indicated that gut microbiota egested during 
infected sandfly bites is an important determinant of Leishmania dissemination via trigger-
ing of inflammasomes, leading to IL-1β production that sustains the neutrophilic infiltrate 
harboring the parasites [11].
3. Current vaccination and immunotherapeutic approach
A major challenge to mitigation of this endemic disease is to achieve safe, efficacious and 
low-cost prophylactic or therapeutic vaccines with long-lasting protection. These vaccines 
should be effective against both stages of the parasite curbing its progression and accompa-
nying pathology that stems from an imbalance between the pathogen and the host immune 
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system. The plethora of candidate vaccines range from the live non-pathogenic vectors to the 
recombinant subunit vaccines, alone or together with adjuvants and/or delivery systems for 
induction of cell-mediated immunity. Some of these include Leishmania-activated C-kinase 
antigen (LACK) [12], Leishmania cysteine peptidase A, B in poly-lactic-co-glycolic acid (PLGA) 
nanoparticles [13], soluble Leishmania antigens in nanoliposomes co-delivered with saponin 
and imiquimod [14], DNA vaccine encoding ornithine decarboxylase [15]. Inclusion of sali-
vary proteins in antileishmanial vaccines has been reported to result in a synergistic protec-
tive effect [16]. A live recombinant amastigote 2 antigen vaccine vector using Trypanosoma 
cruzi non-virulent strain, and live attenuated centrin gene–deleted Leishmania donovani [17] 
have been reported to induce strong T cell-mediated protective immune responses against VL 
and hence could represent promising alternatives for translation to human clinical trials [18]. 
Recombinant small myristoylated protein-3, a virulence factor has been found to be immu-
nogenic in both mice and humans, with induction of protective immunity against murine VL 
[19]. In case of CL, intranasal immunization has been found to reduce numbers of CD4+Foxp3+ 
regulatory T cells with increased Th1 response and associated protection [20].
Immunotherapy on the other hand has been found to promote sterilizing cure. However, 
immunotherapeutic intervention with L. amazonensis antigens plus saponin was not found 
to maintain long-lasting low parasitism in dogs naturally infected with Leishmania infantum 
[21]. Therapy with anti-PDL-1 antibody has been found to promote parasite clearance with 
concomitant induction of protective immunity against VL by inhibiting autophagy, that is 
hijacked by Leishmania [22]. Immunotherapeutic approach with Th1 stimulating antigens 
(aldolase, enolase, p45 and triose phosphate isomerase) has also been attempted [23].
An emerging therapeutic modality for CL is photodynamic therapy of zinc porphyrin that 
results in loss of plasma membrane integrity and hyperpolarization of the mitochondrial 
membrane potential [24].
4. Therapeutic targets and inhibitors
Identification of new drug targets can contribute towards designing inhibitors and strengthen 
the pipeline for disease elimination. DNA topoisomerases that control the over- or under-
winding of DNA have been reported as deadly targets for topoisomerase inhibitors that may 
act as potential antileishmanial drugs [25]. Computational tools using in silico approaches 
targeting key enzymes in metabolic pathways of Leishmania have led to identification of 
several potential druggable targets such as cytochrome P450 sterol 14α-demethylase [26], 
dihydrofolate reductase-thymidylate synthase [27], methylglyoxal degradation superpath-
way [28], trypanothione reductase [29]. Trypanothione reductase is absent in humans and 
neutralizes the reactive oxygen species generated inside the infected macrophages. Inhibitors 
such as chalcones that block the activity of these trypanosomatid enzymes may be effective 
in treatment of leishmaniasis [29]. β-carbonic anhydrase [30], acid phosphatases [31], uracil 
DNA glycosylase [32] and Type 2 NADH dehydrogenase [33] are other potential therapeutic 
targets that are being explored. NLR (NOD-Like Receptor) family member NOD2 has also 
been implicated as an essential therapeutic target [34].
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5. Natural products as source of antileishmanial drugs
In view of looming chemotherapeutic drug resistance, natural products and scaffolds from 
medicinal plants are being emphasized as leads for drug discovery. Plant-based bioactive 
compounds have merit over synthetic compounds, considering their unique structural vari-
ety, providing an unlimited source of molecules and biological activities [35]. A host of plant 
extracts or oils and their phytoconstituents (alkaloids, terpenoids, quinones, flavonoids, 
saponins, phenylpropanoids, flavonoids, lignoids, naphthoquinones, iridoids, and more) 
have shown promise in vitro and/or in vivo [36–41]. In some cases, the leishmanicidal effect is 
potentiated by immunomodulation [3, 42]. Besides plants, secondary metabolites from micro-
organisms such as fungi [43] and marine organisms have also been reported. Plant defensins 
have been found to eliminate Leishmania parasites via plasma membrane perturbation, mito-
chondrial membrane collapse, and reactive oxygen species induction [44].
Antimicrobial peptides have been reported to improve the therapeutic outcome of anti-
leishmanial drugs [45]. Synergistic drug-natural product combinations have also been 
explored [46, 47].
6. Nanomedicines
In recent years, numerous advances in drug discovery have been made for treating 
leishmaniasis, exploiting nanotechnological approaches to target the immune cell pha-
golysosomes that harbors the Leishmania amastigotes. A plethora of nanoparticles have 
been reported to elicit protection with modulation of the immune response via reduc-
tion in anti-inflammatory cytokine IL-10, and increased nitric oxide production [48]. 
Recently, antileishmanial activity of sulphonamide nanoemulsions have been reported 
that target the leishmanial β-carbonic anhydrase [30]. Linalool-loaded gold nanoparticles 
have also been found to exhibit therapeutic effectiveness against Leishmania [49]. A short-
course AmBisome regimen has been found to be safe and effective in the treatment of 
clinically diagnosed PKDL patients in Bangladesh, and may be considered as a viable 
option for routine programmatic use, contributing towards the VL elimination drive [50]. 
Biodegradable PLGA microparticles loaded with an antileishmanial nitrochalcone has 
proved therapeutic effectiveness when administered subcutaneously in BALB/c mice with 
cutaneous lesions [51].
Green nanoparticles, that is, plant-based synthesis of nanoparticles have an upper edge 
over the synthetic nanoparticles owing to their biosynthesis being rapid, eco-friendly, non-
pathogenic and economical. An array of biogenic nanoparticles from plant extracts has been 
reported to have antileishmanial activity with boosting of anti-oxidant activity [52, 53].
Miltefosine- and ketoconazole-loaded nanoniosomes with improved antileishmanial activity 
have also been reported [54]. AmBisome-miltefosine combination therapy for VL-HIV co-
infected patients has been reported in Ethiopia with 83.8% cure rate [55].
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7. Diagnosis of leishmaniasis
A definitive diagnosis of leishmaniasis is crucial to guide timely and appropriate therapy. The 
disease is often confused with other co-endemic diseases and HIV co-infections may result in 
atypical clinical presentation [4]. Differential diagnosis of VL should be considered in patients 
of endemic areas after organ transplantation [56]. This underscores the need for highly sensitive 
and specific diagnostic modalities. In this regard, molecular techniques such as real-time poly-
merase chain reaction (qPCR)-based methods are gaining ground for detection and quantifica-
tion of Leishmania as well as for species identification [57]. However, to rule out false negatives, 
combination of two PCR techniques is advisable in patients with cutaneous lesions [58]. For 
VL, serological diagnosis with recombinant antigen rK39-based immunochromatography and 
direct agglutination test based on the whole parasite antigens have been reported to have high 
sensitivity and specificity [59]. Nonetheless, amastigote detection in bone marrow aspirates and 
positive rK39 immunochromatographic test should be further validated by nested PCR [60]. 
Recently, a loop-mediated isothermal amplification (LAMP) assay based on 18S rDNA and the 
conserved region of minicircle kDNA has been implicated with high sensitivity for visceral as 
well as CL diagnostics [61]. Further, Leishmania urine antigen has been explored as a probable 
biomarker for predicting treatment failure and relapse in VL/HIV-coinfected patients [62].
8. Conclusions and future perspectives
To strengthen the leishmaniasis elimination drive, particular emphasis has to be laid on the 
diagnosis, chemotherapeutics and new targets identification and vaccination strategies for 
control of this endemic disease. This underscores renewed efforts to combat upcoming chal-
lenges in the quest for new drug targets in achieving definitive cure and/or safe, cost-effective 
prophylactic vaccines with long-lasting immunity against leishmaniasis. An effective thera-
peutic vaccine may further boost the immunosuppressed state and thus control the visceral-
izing form of leishmaniasis that is mainly harbored in the South Asian region.
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